Covaxin to use ViroVax’s adjuvant for long lasting immunity

Vaccine maker Bharat Biotech on Monday announced its novel coronavirus vaccine (under development) Covaxin, which was approved for human trials, will use adjuvant Alhydroxiquim-II to boost immune response and longer lasting immunity.

According to a press release issued by the city-based vaccine innovator, the technology is being used under a licensing agreement with Kansas-based ViroVax LLC.

Covaxin is an inactivated vaccine derived from a strain of SARS-CoV-2 virus, isolated at the National Institute of Virology (NIV), Pune, an Indian virology research institute.

The inactivated virus is formulated with ViroVax's adjuvant to produce the vaccine candidate, it said.

Bharat Biotech is currently conducting Phase II human trials of Covaxin after receiving approval from the Drug Controller General of India (DCGI). .........................................................................